Elicio Therapeutics Inc
ELTX
NASDAQ
Biotechnology
$3.09
USD
-0.06 (-1.90%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $73.92M
Volume 152.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-40.19M
TTM
+21.6%
YoY
Operating Cash Flow
$-38.48M
TTM
-9.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.0 | 3.1 | 3.0 | 3.8 | 3.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.7 | 10.1 | 8.0 | 8.8 | 10.6 |
Operating Income | -10.7 | -10.1 | -8.0 | -8.8 | -10.6 |
EBITDA | -10.7 | -10.0 | -8.0 | -8.8 | -10.6 |
Other Income / Expense | -0.5 | -0.4 | -1.8 | 1.3 | -1.0 |
Total Other Income / Expense | -0.5 | -0.5 | -2.0 | 1.1 | -1.2 |
Income Before Income Taxes | -11.2 | -10.6 | -10.1 | -7.7 | -11.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -11.2 | -10.6 | -10.1 | -7.7 | -11.8 |
Consolidated Net Income / Loss | -11.2 | -10.6 | -10.1 | -7.7 | -11.8 |
Net Income Attributable to Common Shareholders | -11.2 | -10.6 | -10.1 | -7.7 | -11.8 |
Basic EPS | -$0.87 | -$0.66 | -$0.60 | -$0.50 | -$0.65 |
Diluted EPS | -$0.87 | -$0.66 | -$0.60 | -$0.50 | -$0.65 |
Basic Shares Outstanding | 13.0M | 16.1M | 16.7M | 15.5M | 18.2M |
Diluted Shares Outstanding | 13.0M | 16.1M | 16.7M | 15.5M | 18.2M |